MedTrace Logo

Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and Asthma

NCT05476484 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 49844

Last updated 2023-08-02

No results posted yet for this study

Summary

To assess the impact of SQ SLIT-tablets (SQ Grass SLIT-tablet and SQ HDM SLIT-tablet) in Danish and Swedish allergic rhinitis (AR) patients, with or without asthma, between 2007-2020.

Conditions

  • Allergy
  • Allergic Rhinitis
  • Asthma

Interventions

DRUG

SQ SLIT-tablet

SQ grass SLIT-tablet and/or SQ house dust mite SLIT-tablet

Sponsors & Collaborators

  • Quantify Research

    collaborator UNKNOWN

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Julie F Rask Larsen, MD PhD · ALK

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2024-06-30
Completion
2024-06-30
FDA Drug
Yes

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05476484 on ClinicalTrials.gov